Skip to NavigationSkip to content

New blood cancer treatment appears successful for most trial patients

Published on 12/12/22 at 10:58am

A new and experimental immunotherapy treatment has appeared successful in treating patients with multiple myeloma in an ongoing phase 1/2 clinical trial. The blood cancer treatment has seen successful response rates in 73% of patients, and an application has been submitted to the FDA to bring the drug to market.

The new immunotherapy is known as talquetamab and is a bispecific T cell engager antibody, which is a relatively new form of treatment. The antibody is engineered to bind to CD3 receptors on immune T cells, and GPRC5D receptors found in high levels on cancerous plasma cells. The drug essentially aims to connect immune cells with cancer cells, placing a target on the cancer cells while giving the immune cells a map to the cancerous cell.

The phase 1/2 trial for talquetamab included several hundred multiple myeloma patients, with two doses of the drug on either a weekly or fortnightly dosing schedule. Across all of the groups, the trial saw 73% of patients responding well to the treatment.

Johnson & Johnson said in a press release, “With a median follow-up of 14.9 months (range 0.5+ to 29.0), 74.1% of patients treated at the SC 0.4mg/kg dose administered weekly achieved a response, 59.4% achieved a very good partial response or better, 33.6% achieved a complete response or better and 23.8% achieved a stringent complete response.”

Sen Zhuang, vice president of clinical R&D at Janssen Research & Development, commented: “Following our recent Biologics License Application submission to the US FDA, we look forward to working with the agency to make this available as a treatment option in the short term and continuing our longer-term investigations of talquetamab as we aim to develop additional options for patients with this complex blood cancer.”

 

Betsy Goodfellow


Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches